Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06337812 · ClinicalTrials.gov registry record · NA
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
A NA study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, sponsored by University of Michigan.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06337812: Recruiting NA study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, sponsored by University of Michigan.
NCT06337812 is a NA study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by University of Michigan. The registered enrollment target is 30 participants, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06337812, a NA study of Type 2 Diabetes and Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by University of Michigan.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria make more short chain fatty acids, a byproduct the team thinks may benefit participant's health.
Primary Outcome
Stool will be analyzed.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Potato Starch
Study Locations (1)
Michigan
- University of Michigan - Ann Arbor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2026-12 |
| Phase | NA |
What NCT06337812 shows while recruiting
NCT06337812 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,924-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which Potato Starch is the first listed.
NCT06337812 reports a single indexed study location in Michigan.
Frequently Asked Questions
What is clinical trial NCT06337812 about?
NCT06337812 is a clinical study titled "Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)". The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut microbiome. The study team also wants to understand if adding potato starch to participant's diet helps these bacteria mak...
What is the current status of trial NCT06337812?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2024-04-01. Estimated completion is 2026-12.
What conditions does trial NCT06337812 study?
This clinical trial studies the following conditions: Type 2 Diabetes, Heart Failure With Preserved Ejection Fraction.
What interventions are being tested in trial NCT06337812?
The interventions under investigation include: Potato Starch (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06337812?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06337812 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06337812's enrollment target sits among peer trials
30 256th of 327 higher than 57 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI